Skip to main content
ArticleOPEN ACCESS

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus

Diabetes Therapy
DOI: 10.1007/s13300-020-00894-y
37Citations
Citations of this article
153Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of action and mode of administration. This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability.

Author supplied keywords

Cite

CITATION STYLE

APA

Kalra, S., & Sahay, R. (2020, September 1). A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. Diabetes Therapy. Adis. https://doi.org/10.1007/s13300-020-00894-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free